Cipla Limited — PPTs, 25-07-2025: Investor Presentation

**1. Financial Highlights:**

Cipla's Q1FY26 revenue grew 4% YoY to INR 6,957 Cr. EBITDA rose 4% to INR 1,778 Cr (25.6% margin), with Profit After Tax jumping 10% YoY to INR 1,298 Cr. The company maintains a strong balance sheet, featuring INR 10,838 Cr in cash and low overall debt.

**2. Strategic Initiatives & Growth Drivers:**

Strategic focus on chronic therapies, especially respiratory, led to new triple-therapy inhaler launches like Voltido Trio. Cipla expanded its portfolio with new anti-diabetes product Empa and CNS brand acquisitions. North America's pipeline includes gAdvair, gSymbicort, and upcoming peptide assets.

**3. Business Developments:**

Seven new products were launched in India, including an Orthopaedics entry. Oncology drugs Nano Paclitaxel and Nilotinib were introduced in North America. Cipla anticipates its first US biosimilar product launch in Q2 FY26.

**4. Market Position & Competitive Advantage:**

Cipla holds a #2 rank in India's chronic segment, with its respiratory brands dominating. Albuterol is #1 in the U.S. MDI market (19.5% share). Key consumer brands Nicotex and Omnigel lead their respective Indian markets. The company also ranks #2 in South Africa's prescription market.

**5. Investor Implications:**

Strong Q1FY26 financials, a strategic product pipeline, and robust market positions collectively signal positive growth potential. A healthy balance sheet offers financial flexibility. Investors should closely monitor the successful execution of new launches and pipeline advancements.